Recursion Pharmaceuticals is trading 10.24% down at $3.83 amid biotech-sector weakness, with no clear company-specific catalyst identified for the October 8, 2026 decline. - The XBI ETF was down 1.87% in late-morning trading, consistent with sector weakness. - Its Morgan Stanley healthcare conference appearance and reported ARK purchases do not establish a direct catalyst.